Till date, the vaccine is approved in Mexico, The Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore.
The vaccine was developed by Sanofi Pasteur. According to WHO, it was first licensed in Mexico in December 2015 for use in individuals 9-45 years of age living in endemic areas. It is given as a 3-dose series on a 0/6/12 month schedule.
“We’re pleased to see the growing medical and public health recognition for the vaccine. With this new tool in hand, public health communities in dengue-endemic countries now have additional means to achieve the WHO objectives for 50 per cent reduction in mortality and 25 per cent reduction in morbidity due to dengue by 2020,” Su Peing Ng, head of Global Medical Affairs for Sanofi Pasteur, said in a statement.
Generally, recovery takes less than two to seven days. However, in some cases, the disease develops into the life-threatening dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets or even death.
This year, PTI reported that at least 21 deaths due to dengue were reported at various hospitals, including nine at AIIMS, in the national capital. Also, dengue cases crossed the 2,100 mark in the city.